529 related articles for article (PubMed ID: 10929918)
1. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.
Ponssen HH; Elte JW; Lehert P; Schouten JP; Bets D
Clin Ther; 2000 Jun; 22(6):709-18. PubMed ID: 10929918
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
3. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
4. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
Schwartz SL; Ratner RE; Kim DD; Qu Y; Fechner LL; Lenox SM; Holcombe JH
Clin Ther; 2008 May; 30(5):858-67. PubMed ID: 18555933
[TBL] [Abstract][Full Text] [Related]
5. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
[TBL] [Abstract][Full Text] [Related]
6. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double-blind randomized placebo-controlled trial.
Douek IF; Allen SE; Ewings P; Gale EA; Bingley PJ;
Diabet Med; 2005 May; 22(5):634-40. PubMed ID: 15842521
[TBL] [Abstract][Full Text] [Related]
7. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
8. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
9. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study.
Hohberg C; Pfützner A; Forst T; Lübben G; Karagiannis E; Borchert M; Schöndorf T
Diabetes Obes Metab; 2009 May; 11(5):464-71. PubMed ID: 19422402
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus.
Hermann LS; Bitzén PO; Kjellström T; Lindgärde F; Scherstén B
Diabete Metab; 1991 May; 17(1 Pt 2):201-8. PubMed ID: 1936477
[TBL] [Abstract][Full Text] [Related]
11. [Cardiovascular risk factors and treatment with insulin in type II diabetic patients in whom oral hypoglycemic drugs have failed].
Calle Pascual AL; Calle Fernández JR
Med Clin (Barc); 1993 Jun; 101(5):165-7. PubMed ID: 8332008
[TBL] [Abstract][Full Text] [Related]
12. Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus.
Hermann LS; Kjellström T; Nilsson-Ehle P
Diabete Metab; 1991 May; 17(1 Pt 2):174-9. PubMed ID: 1936472
[TBL] [Abstract][Full Text] [Related]
13. The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM).
Elkeles RS
Diabete Metab; 1991 May; 17(1 Pt 2):197-200. PubMed ID: 1936476
[TBL] [Abstract][Full Text] [Related]
14. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus.
Nagi DK; Ali VM; Yudkin JS
Diabet Med; 1996 Aug; 13(8):753-7. PubMed ID: 8862952
[TBL] [Abstract][Full Text] [Related]
15. Added benfluorex in obese insulin-requiring type 2 diabetes.
Leutenegger M; Bauduceau B; Brun JM; Guillon-Metz F; Martin C; Nicolino-Peltier C; Richard JL; Vannereau D
Diabetes Metab; 1998 Feb; 24(1):55-61. PubMed ID: 9534010
[TBL] [Abstract][Full Text] [Related]
16. Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity.
Kar P; Laight D; Rooprai HK; Shaw KM; Cummings M
Diabet Med; 2009 May; 26(5):526-31. PubMed ID: 19646193
[TBL] [Abstract][Full Text] [Related]
17. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD.
Noury J; Nandeuil A
Diabete Metab; 1991 May; 17(1 Pt 2):209-12. PubMed ID: 1936478
[TBL] [Abstract][Full Text] [Related]
18. Metformin, a promising oral antihyperglycemic for the treatment of noninsulin-dependent diabetes mellitus.
Wildasin EM; Skaar DJ; Kirchain WR; Hulse M
Pharmacotherapy; 1997; 17(1):62-73. PubMed ID: 9017766
[TBL] [Abstract][Full Text] [Related]
19. [Gliclazide and metformin combination in patients with type 2 diabetes. Preliminary data].
Galeone F; Fiore G; Arcangeli A; Mannucci E
Minerva Endocrinol; 1998 Sep; 23(3):71-5. PubMed ID: 10063324
[TBL] [Abstract][Full Text] [Related]
20. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
Goo AK; Carson DS; Bjelajac A
J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
